Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-02T18:56:02.777Z Has data issue: false hasContentIssue false
  • English
  • Français

III. Plasma Growth Hormone and Prolactin Responses to Apomorphine

Published online by Cambridge University Press:  29 January 2018

Tamara Kolakowska ,
Michael Gelder  and
Sheila Fraser
Tamara Kolakowska
Affiliation:
University of Oxford, Department of Psychiatry, Littlemore Hospital Research Unit, Oxford, OX4 4XN
Michael Gelder
Affiliation:
University of Oxford, Department of Psychiatry, Littlemore Hospital Research Unit, Oxford, OX4 4XN
Sheila Fraser
Affiliation:
University of Oxford, Department of Psychiatry, Littlemore Hospital Research Unit, Oxford, OX4 4XN
Get access Rights & Permissions [Opens in a new window]

Summary

Hormonal responses to apomorphine 0.005 and/or 0.01 mg/kg body weight were studied in 17 schizophrenic patients during their routine treatment with neuroleptic drugs. Plasma growth hormone (GH) rose in 9 of the 20 tests and in 4 of these GH peak exceeded 5 ng/ml. This preserved GH response to apomorphine was significantly but weakly associated with lower daily doses of neuroleptics. It was unrelated to the extrapyramidal side-effects, plasma prolactin (PRL) level, duration of treatment or its therapeutic effect.

In 13 of the 20 tests, plasma PRL declined by more than 20 per cent of the baseline level. This was similar to the fall in PRL observed after placebo in the group studied previously. The absolute decline in plasma PRL following apomorphine correlated positively with the baseline PRL concentration and was unrelated to the daily doses of neuroleptics or to any other variable considered.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 139 , Issue 5 , November 1981 , pp. 408 - 412
Copyright
Copyright © Royal College of Psychiatrists, 1981 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Davis, J. M. (1976) Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry, 33, 855–66.CrossRefGoogle ScholarPubMed
Ettigi, P., Nair, N. P. V., Lal, S., Cervantes, P. & Guyda, H. (1976) Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. Journal of Neurology, Neurosurgery and Psychiatry, 39, 870–6.CrossRefGoogle ScholarPubMed
Kolakowska, T., Orr, M. W., Gelder, M. G., Heggie, M., Wiles, D. H. & Franklin, M. (1979) Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: A replication. British Journal of Psychiatry, 135, 352–9.Google Scholar
Kolakowska, T., Gelder, M. G. & Orr, M. W. (1980) Drug-related and illness-related factors in the outcome of chlorpromazine treatment: Testing a model. Psychological Medicine, 10, 335–43.Google Scholar
Kolakowska, T., Fraser, S., Franklin, M. & Knox, J. (1981) Neuroendocrine tests during treatment with neuroleptic drugs: I. Plasma prolactin response to chlorpromazine challenge. Psychopharmacology, 72, 283–5.Google Scholar
Kolakowska, T., Braddock, L., Wiles, D., Franklin, M. & Gelder, M. (1981) Neuroendocrine tests during treatment with neuroleptic drugs. I. Plasma prolactin response to haloperidol challenge. British Journal of Psychiatry, 139, 400–12.CrossRefGoogle ScholarPubMed
Lal, S., De La Vega, C. E., Sourkes, T. L. & Friesen, H. G. (1973) Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle stimulating hormone levels in human serum. Journal of Clinical Endocrinology and Metabolism, 37, 719–24.Google Scholar
Lal, S., Guyda, H. & Bikadoroff, S. (1977) Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men. Journal of Clinical Endocrinology and Metabolism, 44, 766–70.CrossRefGoogle ScholarPubMed
Meltzer, H. Y., Good, D. J., Fang, V. S., Schyve, P. & Young, M. (1976) Dopamine and schizophrenia. Lancet, iii, 1142.Google Scholar
Nair, N. P., Lal, S., Cervantes, P., Yassa, R. & Guyda, H. (1979) Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia. Neuropsychobiology, 5, 136–42.Google Scholar
Pandey, G. N., Garver, D. L., Tamminga, C., Ericksen, S. I., Ali, S. I. & Davis, J. M. (1977) Postsynaptic supersensitivity in schizophrenia. American Journal of Psychiatry, 134, 518–22.Google Scholar
Rotrosen, J., Angrist, B., Clark, C., Gershon, S., Halpern, F. S. & Sachar, E. J. (1978) Suppression of prolactin by dopamine agonists in schizophrenics and controls. American Journal of Psychiatry, 135, 949–51.Google Scholar
Rotrosen, J., Angrist, B., Gershon, S., Paquin, J., Branchey, L., Oleshansky, M., Halpern, F. & Sachar, E. J. (1979) Neuroendocrine effects of apomorphine: Characterization of response patterns and application to schizophrenia research. British Journal of Psychiatry, 135, 444–56.Google Scholar
Tamminga, C. A., Smith, R. C., Pandey, G., Frohman, L. A. & Davis, J. M. (1977) A neuroendocrine study of supersensitivity in tardive dyskinesia. Archives of General Psychiatry, 34, 1199–203.Google Scholar
Weiss-Brummer, J. (1980) Effect of neuroleptic treatment on human growth hormone release. In Abstracts of the 12th CINP Congress, Goteborg, Sweden, 22—26 June 1980, Article No. 692.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.